Ocular Therapeutix
OCUL
73 hedge funds and large institutions have $96.5M invested in Ocular Therapeutix in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 8 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
13% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $1.05M
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 72 → 73 (+1)
0.21% more ownership
Funds ownership: 53.41% → 53.62% (+0.21%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
33% less capital invested
Capital invested by funds: $144M → $96.5M (-$47.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
+$3.19M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$795K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$255K |
| 5 |
SC
Sculptor Capital
New York
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$3.12M |
| 2 |
Morgan Stanley
New York
|
-$829K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$662K |
| 4 |
CI
Cowen Inc
New York
|
-$456K |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$371K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RPAM
76
Rhenman & Partners Asset Management
Stockholm,
Sweden
| – | -$371K | -40,000 | Closed |
|
|
NFG
77
Next Financial Group
Houston,
Texas
| – | -$363K | -39,200 | Closed |
|
|
CA
78
Corrado Advisors
Ramsey,
New Jersey
| – | -$239K | -25,785 | Closed |
|
|
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$159K | -17,157 | Closed |
|
80
Squarepoint
New York
| – | -$146K | -15,703 | Closed |
|
81
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$102K | -11,000 | Closed |
|
OCUL Hedge Fund Activity: Q3 2017 in Review
73 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2017, worth a combined $96.5M — down 33% from $144M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OCUL positions and 8 closed out — a net gain of 1 holder — while 24 added to existing stakes and 19 trimmed.
The largest buyer was Columbus Circle Investors, adding an estimated $3.19M. The largest seller was JP Morgan Private Wealth Advisors, exiting entirely with an estimated $3.12M sold.
- 73 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2017, up from 72 in Q2 2017.
- Funds reported $96.5M of Ocular Therapeutix stock for Q3 2017, down 33% quarter-over-quarter.
- 9 funds opened new Ocular Therapeutix positions in Q3 2017 and 8 closed out, a net change of +1 holder.
- The largest Ocular Therapeutix buyer in Q3 2017 was Columbus Circle Investors, an estimated $3.19M added.
- The largest Ocular Therapeutix seller in Q3 2017 was JP Morgan Private Wealth Advisors, an estimated $3.12M sold.
Based on aggregated 13F filings for Q3 2017.